Hepatitis C among Predialysis Patients: Prevalence and Characteristics in a Large Cohort of PatientsLemos L.B.a · Perez R.M.c · Lemos M.M.b · Draibe S.A.b · Silva I.S.a · Silva A.E.B.a · Ferraz M.L.G.a
Divisions of aGastroenterology and bNephrology, Federal University of Sao Paulo, Sao Paulo, and cDepartment of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: The factors associated with hepatitis C virus (HCV) infection in predialysis patients need to be better investigated. The aims of this study were to evaluate the prevalence, risk factors, clinical, biochemical and virological characteristics of chronic HCV infection in predialysis patients. Methods: Anti-HCV antibodies were determined in a large cohort of predialysis patients. Epidemiological and laboratorial characteristics of HCV infection were evaluated in predialysis patients and this group was matched to a control group consisting of predialysis patients without viral infection (1:3) and compared in terms of risk factors and alanine aminotransferase (ALT) levels. Logistic regression analysis was applied to identify variables independently associated with chronic HCV infection. Results: A total of 1,041 patients (61% males) with a mean age of 61 ± 15 years and mean creatinine clearance of 36 ± 18 ml/min were included. Forty-one (3.9%) patients were anti-HCV positive and, of these, 39 (95%) presented viremia. Predialysis patients with HCV more frequently showed a history of blood transfusion before 1992 (66.7 vs. 10.3%; p < 0.001) and major surgeries (53.8 vs. 17.1%; p < 0.001), a higher proportion of undetermined etiology of kidney disease (43.6 vs. 17.1%; p = 0.001), and higher ALT levels (1.3 vs. 0.4 ×ULN; p < 0.001). History of blood transfusion before 1992 (p < 0.001; OR: 19), intravenous drug abuse (p = 0.002; OR: 69) and ALT levels (p < 0.001; OR: 50) were the variables that were independently associated with chronic HCV infection. The accuracy of ALT in detecting HCV infection was 92%. The most prevalent HCV genotype was 1b (48.7%) and 56.5% of patients presented high HCV viral load. Conclusion: Chronic HCV infection among predialysis patients is related to increased parenteral exposure. Elevated ALT levels suggest the need for HCV screening as part of the predialysis care since ALT seems to be a good marker of this infection.
© 2008 S. Karger AG, Basel
- Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ: Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998;32:629–634.
- Fehr T, Ambuhl PM: Chronic hepatitis virus infections in patients on renal replacement therapy. Nephrol Dial Transplant 2004;19:1049–1053.
- Mitwalli A, al-Mohaya S, al Wakeel J, el Gamal H, Rotimi V, al-Zeben A, al-Aska A: Hepatitis C in chronic renal failure patients. Am J Nephrol 1992;12:288–291.
- Fabrizi F, Marcelli D, Bacchini G, Guarnori I, Erba G, Locatelli F: Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant 1994;9:780–784.
- Garcia-Valdecasas J, Bernal C, Garcia F, Cerezo S, Umana WO, von Albertini B, Kimmel PL: Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol 1994;5:186–192.
- Kumar H, Naqvi SA, Ahmed A, Hamid S: Hepatitis-C virus antibodies (anti HCV) in haemodialyzed versus non-dialyzed patients. J Pak Med Assoc 1994;44:28–30.
- Ilcol B, Ozener C, Avsar M, Ilcol Y, Lawrence R, Ozer A, Cirakoglu B, Akoglu E: Hepatitis C infection in patients with chronic renal failure receiving conservative therapy (letter). Nephrol Dial Transplant 1997;12:626.
- Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, Locatelli F: Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001;38:1009–1015.
- Lopez-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolome J, Sanz P, Selgas R, Carreno V: Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001;63:103–107.
- Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, Aljama P: Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004;43:685–689.
- Bergman S, Accortt N, Turner A, Glaze J: Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005;45:684–689.
- Cendoroglo Neto M, Manzano SI, Canziani ME, Silva AE, Cirenza LF, Sesso RdC, Ajzen H, Draibe SA: Environmental transmission of hepatitis B and hepatitis C viruses within the hemodialysis unit. Artif Organs 1995;19:251–255.
- de Lamballerie X, Olmer M, Bouchouareb D, Zandotti C, De Micco P: Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996;49:296–302.
- Olmer M, Bouchouareb D, Zandotti C, de Micco P, de Lamballerie X: Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997;47:263–270.
- Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Goudeau A: Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998;36:3040–3043.
- Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, Mulhim KA: Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control 2003;31:26–33.
- Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J: Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol 2004;25:584–590.
- Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, Kakavas J, Kalapothaki V, Boletis J, Hatzakis A: Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005;45:334–343.
- Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G: Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000;69:1479–1484.
- K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–S266.
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
- Perez RM, Ferraz ML, Figueiredo MS, Contado D, Koide S, Ferreira AP, Cendoroglo Neto M, Medina Pestana JO, Silva AE: Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003;69:489–494.
- Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002;105:1257–1267.
- CDC: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1–39.
Focaccia R, da Conceicao OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, Lomar AV, Lorenco R, Vieira De Souza F, Kiffer CR, Santos EB, Gonzales MP, Saez-Alquezar A, Riscal JR, Fischer D: Estimated prevalence of viral hepatitis in the general population of the Municipality of Sao Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998;2:269–284.
- Salako BL, Ayodele OE, Kadiri S, Arije A: Prevalence of hepatitis B and C viruses in pre-dialysis patients with chronic renal failure. Afr J Med Med Sci 2002;31:311–314.
- Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995;69:459–465.
- Galan F, Perez-Gracia MT, Lozano A, Benavides B, Fernandez-Ruiz E, Rodriguez-Iglesias MA: A 3-year follow-up of HCV-RNA viraemia in haemodialysis patients. Nephrol Dial Transplant 1998;13:1211–1214.
- Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S, Mousa M, Gitnick G: Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000;35:122–129.
- Halfon P, Khiri H, Feryn JM, Sayada C, Chanas M, Ouzan D: Prospective virological follow-up of hepatitis C infection in a haemodialysis unit. J Viral Hepat 1998;5:115–121.
- Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S: Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 2000;95:490–496.
- Fabrizi F, Bunnapradist S, Lunghi G, Martin P: Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol 2003;16:467–475.
- Beutler E, Gelbart T, Kuhl W: Interference of heparin with the polymerase chain reaction. Biotechniques 1990;9:166.
- Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI: Effect of heparin on polymerase chain reaction. Lancet 1994;343:1509–1510.
- Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I: Effects of heparin on polymerase chain reaction for blood white cells. J Clin Lab Anal 1999;13:133–140.
- Qian KP, Natov SN, Pereira BJ, Lau JY: Hepatitis C virus mixed genotype infection in patients on haemodialysis. J Viral Hepat 2000;7:153–160.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.